Ieq Capital LLC lifted its position in Abbott Laboratories (NYSE:ABT – Free Report) by 2.0% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 108,990 shares of the healthcare product maker’s stock after acquiring an additional 2,154 shares during the quarter. Ieq Capital LLC’s holdings in Abbott Laboratories were worth $11,325,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently made changes to their positions in the company. Intech Investment Management LLC increased its position in shares of Abbott Laboratories by 10.0% during the second quarter. Intech Investment Management LLC now owns 35,323 shares of the healthcare product maker’s stock valued at $3,670,000 after acquiring an additional 3,200 shares during the last quarter. Delaney Dennis R increased its position in shares of Abbott Laboratories by 0.4% during the 2nd quarter. Delaney Dennis R now owns 59,366 shares of the healthcare product maker’s stock valued at $6,169,000 after purchasing an additional 210 shares during the last quarter. MQS Management LLC raised its stake in shares of Abbott Laboratories by 3.8% during the 2nd quarter. MQS Management LLC now owns 6,786 shares of the healthcare product maker’s stock worth $705,000 after purchasing an additional 250 shares during the period. XTX Topco Ltd boosted its holdings in shares of Abbott Laboratories by 697.2% in the 2nd quarter. XTX Topco Ltd now owns 33,331 shares of the healthcare product maker’s stock worth $3,463,000 after buying an additional 29,150 shares during the last quarter. Finally, Concorde Asset Management LLC grew its position in Abbott Laboratories by 5.6% during the second quarter. Concorde Asset Management LLC now owns 2,277 shares of the healthcare product maker’s stock valued at $237,000 after buying an additional 120 shares during the period. Hedge funds and other institutional investors own 75.18% of the company’s stock.
Insider Buying and Selling
In other Abbott Laboratories news, CEO Robert B. Ford sold 141,679 shares of the firm’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $116.41, for a total value of $16,492,852.39. Following the sale, the chief executive officer now owns 220,059 shares of the company’s stock, valued at approximately $25,617,068.19. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 1.10% of the stock is owned by company insiders.
Analyst Ratings Changes
Abbott Laboratories Trading Down 0.6 %
Shares of Abbott Laboratories stock opened at $114.15 on Friday. The company’s 50-day moving average price is $110.32 and its 200-day moving average price is $108.64. The company has a market cap of $198.58 billion, a price-to-earnings ratio of 35.56, a PEG ratio of 2.90 and a beta of 0.72. Abbott Laboratories has a 12-month low of $89.67 and a 12-month high of $121.64. The company has a current ratio of 1.68, a quick ratio of 1.18 and a debt-to-equity ratio of 0.33.
Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its quarterly earnings results on Thursday, July 18th. The healthcare product maker reported $1.14 EPS for the quarter, beating the consensus estimate of $1.10 by $0.04. The firm had revenue of $10.38 billion during the quarter, compared to the consensus estimate of $10.37 billion. Abbott Laboratories had a net margin of 13.65% and a return on equity of 20.18%. The business’s quarterly revenue was up 4.0% compared to the same quarter last year. During the same period last year, the firm earned $1.08 EPS. On average, equities analysts expect that Abbott Laboratories will post 4.66 earnings per share for the current fiscal year.
Abbott Laboratories Profile
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
See Also
- Five stocks we like better than Abbott Laboratories
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- Stock Average Calculator
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- What Are Dividend Achievers? An Introduction
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.